PeptiDream Expands its Partnership with Novartis for Peptide Discovery
Shots:
- PeptiDream has expanded its partnership with Novartis previously signed in 2019 for the discovery of peptides to be used as peptide-drug conjugate
- The partnership will leverage PeptiDream’s Peptide Discovery Platform System (PDPS) technology to discover new macrocyclic peptides for Novartis-selected targets to be used in radionuclide conjugation and other therapeutic/diagnostic applications
- Under the partnership, PeptiDream is entitled to receive $180M upfront, $2.71B development, regulatory & commercial milestones along with net-sales-based tiered royalties
Ref: PeptiDream | Image: Novartis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
